Company / Accounts Receivable
AbbVie Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$12.6B
FY2025
5-year range
$10.0B / $12.6B
FY2021-FY2025
Trend
+15.3%
vs FY2024
Sector context
#3 of 115
Health Care
What the data says
Among 115 Health Care companies, AbbVie is in the top 3% for accounts receivable. Accounts Receivable returned to growth in FY2025 after 2 years of decline, reaching $12.6B.
Based on SEC 10-K filings.
$12.6B in FY2025 with a 5-year CAGR of +7.4%. Ranks 3rd among 115 companies in Health Care.
Improved from $11.2B to $12.6B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +3.8%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 115This company $12.6B Sector average $1.1B
▼
+1024.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, accounts receivable increased 15.3% year-over-year.
- Ranks #3 out of 115 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.6B | +15.3% |
| FY2024 | $10.9B | -2.1% |
| FY2023 | $11.2B | -0.9% |
| FY2022 | $11.3B | +12.8% |
| FY2021 | $10.0B | +13.1% |
| FY2020 | $8.8B | +62.5% |
| FY2019 | $5.4B | +0.8% |
| FY2018 | $5.4B | +5.8% |
| FY2017 | $5.1B | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026